Wuhan Brightrun Pharmaceutical Technology Co., Ltd.
BRH
Product
News
In the field of diabetes drug development and treatment monitoring, accurately measuring the blood concentrations of insulin and its analogs—such as human insulin, aspart insulin, glargine insulin, and degludec insulin—presents a central challenge. These compounds, characterized by their large molecular weights, significant endogenous interference, and extremely low exposure levels, place nearly exacting demands on analytical methods. Thanks to its deep-rooted technological expertise, Wuhan Brightrun Pharmaceutical Technology Co., Ltd. has successfully overcome these industry hurdles.
Keywords:BoreiHeng Pharmaceutical Technology